Use of 123I-MIBG scintigraphy to assess the impact of carvedilol on cardiac adrenergic neuronal function in childhood dilated cardiomyopathy

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 30, Issue 12, 2003, Pages 1651-1656

  Maunoury, Christophe ^a   Acar, Philippe ^a   Sidi, Daniel ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Cardiomyopathy; Carvedilol; Metaiodobenzylguanidine; Paediatrics; Scintigraphy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; CAPTOPRIL; CARVEDILOL; (3 IODOBENZYL)GUANIDINE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; DIAGNOSTIC AGENT; PROPANOLAMINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADRENERGIC SYSTEM; ARTICLE; CONGESTIVE CARDIOMYOPATHY; DRUG UPTAKE; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART SCINTISCANNING; HUMAN; LONG TERM CARE; MALE; MORBIDITY; MORTALITY; PRESCHOOL CHILD; SCHOOL CHILD; SCINTIANGIOGRAPHY; ADRENERGIC NERVE; CHILD; CLINICAL TRIAL; DRUG EFFECT; GATED IMAGING; INFANT; SCINTISCANNING; TREATMENT OUTCOME;

3-IODOBENZYLGUANIDINE; ADOLESCENT; ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC FIBERS; CARBAZOLES; CARDIOMYOPATHY, DILATED; CHILD; CHILD, PRESCHOOL; FEMALE; GATED BLOOD-POOL IMAGING; HUMANS; INFANT; MALE; PROPANOLAMINES; RADIOPHARMACEUTICALS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0346734288     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-003-1306-y     Document Type: Article

References (43)

1. Taliercio CP, Seward JB, Driscoll DJ, Fisher LD, Gersh BJ, Tajik AJ. Idiopathic dilated cardiomyopathy in the young: clinical profile and natural history. J Am Coll Cardiol 1985; 6:1126-1131.
2. Griffin ML, Hernandez A, Martin TC, Goldring D, Bolman RM, Spray TL, Strauss AW. Dilated cardiomyopathy in infants and children. J Am Coll Cardiol 1988; 11:139-144.
3. Chen S, Nouri S, Balfour I, Jureidini S, Appleton RS. Clinical profile of congestive cardiomyopathy in children. J Am Coll Cardiol 1990; 15:189-193.
4. Guntheroth WG. Congestive cardiomyopathy in children. J Am Coll Cardiol 1990; 15:194-195.
5. Friedman RA, Moak JP, Garson A. Clinical course of idiopathic dilated cardiomyopathy in children. J Am Coll Cardiol 1991; 18:152-156.
6. Gersony WM. The child with dilated cardiomyopathy: prognostic considerations and management decisions. J Am Coll Cardiol 1991; 18:157-158.
7. Wiles HB, McArthur PD, Taylor AB, Gillette PC, Fyfe DA, Matthews JP, Shelton LW. Prognostic features of children with idiopathic dilated cardiomyopathy. Am J Cardiol 1991; 68:1372-1376.
8. Akagi T, Benson LN, Lightfoot NE, Chin K, Wilson G, Freedom RM. Natural history of dilated cardiomyopathy in children. Am Heart J 1991; 121:1502-1506.
9. Matitiau A, Perez-Atayde A, Sanders SP, Sluysmans T, Parness IA, Spevak PJ, Colan SD. Infantile dilated cardiomyopathy. Circulation 1994; 90:1310-1318.
10. Arola A, Tuominen J, Ruuskanen O, Jokinen E. Idiopathic dilated cardiomyopathy in children: prognostic indicators and outcome. Pediatrics 1998; 101:369-376.
11. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effects of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975; 37:1022-1036.
12. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet 1979; 1:1374-1376.
13. Shaddy RE, Tani LY, Gidding SS, Pahl E, Orsmond GS, Gilbert EM, Lemes V. Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: a multi-institutional experience. J Heart Lung Transplant 1999; 18:269-274.
14. Strein K, Sponer G, Muller-Beckmann B, Bartsch W. Pharmacological profile of carvedilol, a compound with beta-blocking and vasodilating properties. J Cardiovasc Pharmacol 1987; 10 (Suppl 11):S33-S41.
15. Metra M, Nardi M, Giubbini R, Dei Cas L. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994; 24:1678-1687.
16. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 1995; 25:1225-1231.
17. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334:1349-1355.
18. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94:2807-2816.
19. Lombardi WL, Gilbert EM. Carvedilol in the failing heart. Clin Cardiol 2001; 24:757-766.
20. Bruns LA, Chrisant MK, Lamour JM, Shaddy RE, Pahl E, Blume ED, Hallowell S, Addonizio LJ, Canter CE. Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. J Pediatr 2001; 138:505-511.
21. Laer S, Mir TS, Behn F, Eiselt M, Scholz H, Venzke A, Meibohm B, Weil J. Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters. Am Heart J 2002; 143:916-922.
22. Azeka E, Franchini Ramires JA, Valler C, Alcides Bocchi E. Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment. J Am Coll Cardiol 2002; 40:2034-2038.
23. Wieland DM, Brown LE, Rogers WL, Worthington KC, Wu JL, Clinthorne NH, Otto CA, Swanson DP, Beierwaltes WH. Myocardial imaging with radioiodinated norepinephrine storage analog. J Nucl Med 1981; 22:22-31.
24. Kline RC, Swanson DP, Wieland DM, Thrall JH, Gross MD, Pitt B, Beierwaltes WH. Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med 1981; 22:129-132.
25. Sisson JC, Shapiro B, Meyers L, Mallette S, Mangner TJ, Wieland DM, Glowniak JV, Sherman P, Beierwaltes WH. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med 1987; 28:1625-1636.
26. Schofer J, Spielmann R, Schubert A, Weber K, Schluter M. Iodine-123 meta-iobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1988; 12:1252-1258.
27. Merlet P, Valette H, Dubois-Randé JL, Moyse D, Duboc D, Dove P, Bourguignon MH, Benvenuti C, Duval AM, Agostini D, Loisance D, Castaigne A, Syrota A. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992; 33:471-477.
28. Imamura Y, Ando H, Mitsuoka W, Egashira S, Masaki H, Ashihara T, Fukuyama T. Iodine-123-metaiodobenzylguanidine images reflect intense myocardial adrenergic nervous activity in congestive heart failure independent of underlying cause. J Am Coll Cardiol 1995; 26:1594-1599.
29. Fukuoka S, Hayashida K, Hirose Y, Shimotsu Y, Ishida Y, Kakuchi H, Eto T. Use of iodine-123 metaiodobenzylguanidine myocardial imaging to predict the effectiveness of beta-blocker therapy in patients with dilated cardiomyopathy. Eur J Nucl Med 1997; 24:523-529.
30. Merlet P, Benvenuti C, Moyse D, Pouillart F, Dubois-Randé JL, Duval AM, Loisance D, Castaigne A, Syrota A. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med 1999; 40:917-923.
31. 123I-metaiodobenzylguanidine uptake. J Nucl Med 2001; 42:49-54.
32. Baliga RR, Narula J, Dec GW. The MIBG tarot: is it possible to predict the efficacy of beta-blockers in congestive heart failure? J Nucl Cardiol 2001; 8:107-109.
33. Yamazaki J, Muto H, Kabano T, Yamashina S, Nanjo S, Inoue A. Evaluation of beta-blocker therapy in patients with dilated cardiomyopathy. Clinical meaning of iodine 123-metaiodobenzylguanidine myocardial single-photon emission computed tomography. Am Heart J 2001; 141:645-652.
34. 123I-MIBG scintigraphic study. J Nucl Med 2000; 41:400-404.
35. Acar P, Merlet P, Iserin L, Bonnet D, Sidi D, Syrota A, Kachaner J. Impaired cardiac adrenergic innervation assessed by MIBG imaging as a predictor of treatment response in childhood dilated cardiomyopathy. Heart 2001; 85:692-696.
36. 123I-MIBG scintigraphic study. J Nucl Med 2000; 41:845-851.
37. Choi JY, Lee KH, Hong KP, Kim BT, Seo JD, Lee WR, Lee SH. Iodine-123 MIBG imaging before treatment of heart failure with carvedilol to predict improvement of left ventricular function and exercise capacity. J Nucl Cardiol 2001; 8:4-9.
38. Kondo C, Nakazawa M, Momma K, Kusakabe K. Sympathetic denervation and reinnervation after arterial switch operation for complete transposition. Circulation 1998; 97:2414-2419.
39. Acar P, Maunoury C, Antonietti T, Bonnet D, Sidi D, Kachaner J. Left ventricular ejection fraction in children measured by three-dimensional echocardiography using a new transthoracic integrated 3D-probe. A comparison with equilibrium radionuclide angiography. Eur Heart J 1998; 19:1583-1588.
40. Maunoury C, Acar P, Sébahoun S, Barritault L. Assessment of normal left ventricular ejection fraction in children with equilibrium radionuclide angiography. European Association of Nuclear Medicine Congress. Barcelona, 1999. Eur J Nucl Med 1999; 26:1175.
41. Huguet F, Fagret D, Caillet M, Piriou A, Besnard JC, Guilloteau D. Interaction of metaiodobenzylguanidine with cardioactive drugs: an in vitro study. Eur J Nucl Med 1996; 23:546-549.
42. Takeishi Y, Atsumi H, Fujiwara S, Takahashi K, Tomoike H. ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure. J Nucl Med 1997; 38:1085-1089.
43. 123I]-metaiodobenzylguanidine uptake after enalapril treatment in patients with chronic heart failure. Heart 1996; 76:218-222.